Agent
Pelacarsen (TQJ230, AKCEA-APO(a)-LRx)
Status Phase 3 complete; Lp(a)HORIZON outcomes trial neutral (AHA 2026, NEJM 7 November 2026); replaced apheresis in Lp(a)FRONTIERS APHERESIS (2026)
A GalNAc3-conjugated second-generation antisense oligonucleotide against LPA mRNA, given as 80 mg subcutaneously every 4 weeks. Lowers Lp(a) by about 80 percent (NEJM 2020) and replaced weekly apheresis in 25 of 26 patients in Lp(a)FRONTIERS APHERESIS (EHJ 2026). Lp(a)HORIZON (8,322 patients analysed), the first Lp(a) outcomes trial, was neutral: Lp(a) down about 78 percent, the primary endpoint 12.3 versus 12.1 percent, hazard ratio 1.02 (NEJM, November 2026).
Mechanism. Binds apo(a) mRNA in hepatocytes and recruits RNase H1 to degrade it; the N-acetylgalactosamine ligand delivers it to the asialoglycoprotein receptor, which is why the dose is a tenth of the unconjugated parent (IONIS-APO(a)Rx).
Milestones. Phase 1 (Tsimikas, Lancet 2015); phase 2 of the conjugated drug (Viney, Lancet 2016; Tsimikas, NEJM 2020); Lp(a)HORIZON started December 2019, completed enrolment (8,323) in 2022 and read out neutral at AHA Scientific Sessions 2026 (Cho et al., NEJM, 7 November 2026; extended analyses in NEJM Evidence); Lp(a)FRONTIERS APHERESIS positive (EHJ 2026); Lp(a)FRONTIERS EXPANSION, 86 percent lowering in US Black/African American and Hispanic participants (AHA 2026, Circ Popul Health Outcomes 2026).
Where this leaves pelacarsen. No cardiovascular benefit was shown despite the expected Lp(a) lowering; serious adverse events were not increased (37.3 versus 41.1 percent), but injection-site and influenza-like reactions were frequent. The trial does not test the deeper lowering of the siRNAs (olpasiran, lepodisiran) or the oral agent muvalaplin, whose outcomes trials continue.
antisensepelacarsenRNA therapeutics
Page updated 10 November 2026.